

AF

IFW 16421

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/633,034
	Filing Date	August 4, 2000
	First Named Inventor	Tsang et al.
	Art Unit	1642
	Examiner Name	L.R. Helms
	Attorney Docket Number	A33081-R 072771.0106
Total Number of Pages in This Submission		


ENCLOSURES (Check all that apply)		
<input checked="" type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input checked="" type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Supplemental Information Disclosure Statement with references 48-54; return receipt postcard.
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Reply to Missing Parts/Incomplete Application	<input type="checkbox"/> Landscape Table on CD	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53		
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name	Baker Botts LLP	Customer No.	21003
Signature			
Printed name	Lisa B. Kole		
Date	11/16/2005	Reg. No.	35,225

CERTIFICATE OF TRANSMISSION/MAILING	
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:	
Signature	
Typed or printed name	Lisa B. Kole
Date	11/16/2005

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2005

Effective 10/01/2004. Patent fees are subject to annual revision.

☐ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180

Complete if Known

Application Number	09/633,034
Filing Date	August 4, 2005
First Named Inventor	Tsang et al.
Examiner Name	L.R. Helms
Art Unit	1642
Attorney Docket No.	A33081-R 072771.0106

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account:

Deposit
Account
Number
Deposit
Account
Name

02-4377

Baker Botts L.L.P.

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) or any underpayment of fee(s)

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code	Small Entity Fee Code	Fee Description	Fee Paid
1001	2001	Utility filing fee	
1002	2002	Design filing fee	
1003	2003	Plant filing fee	
1004	2004	Reissue filing fee	
1005	2005	Provisional filing fee	
SUBTOTAL (1)			(\$) 0

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
-20 =			0
Independent Claims	-3 =		0
Multiple Dependent			0

Large Entity Fee Code	Small Entity Fee Code	Fee Description
1202	2202	Claims in excess of 20
1201	2201	Independent claims in excess of 3
1203	2203	Multiple dependent claim, if not paid
1204	2204	** Reissue independent claims over original patent
1205	2205	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$) 0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code	Fee Code	Fee Description	Fee Paid
1051	2051	Surcharge - late filing fee or oath	
1052	2052	Surcharge - late provisional filing fee or cover sheet	
1053	1053	Non-English specification	
1812	1812	For filing a request for ex parte reexamination	
1804	1804	Requesting publication of SIR prior to Examiner action	
1805	1805	Requesting publication of SIR after Examiner action	
1251	2251	Extension for reply within first month	
1252	2252	Extension for reply within second month	
1253	2253	Extension for reply within third month	
1254	2254	Extension for reply within fourth month	
1255	2255	Extension for reply within fifth month	
1401	2401	Notice of Appeal	
1402	2402	Filing a brief in support of an appeal	
1403	2403	Request for oral hearing	
1451	1451	Petition to institute a public use proceeding	
1452	2452	Petition to revive - unavoidable	
1453	2453	Petition to revive - unintentional	
1501	2501	Utility issue fee (or reissue)	
1502	2502	Design issue fee	
1503	2503	Plant issue fee	
1460	1460	Petitions to the Commissioner	
1807	1807	Processing fee under 37 CFR 1.17(q)	
1806	1806	Submission of Information Disclosure Stmt	180
8021	8021	Recording each patent assignment per property (times number of properties)	
1809	2809	Filing a submission after final rejection (37 CFR 1.129(a))	
1810	2810	For each additional invention to be examined (37 CFR 1.129(b))	
1801	2801	Request for Continued Examination (RCE)	
1802	1802	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 180

SUBMITTED BY

Name (Print/Type)	Lisa B. Kole	Registration No. (Attorney/Agent)	35,225	Telephone	212 408-2628
Signature		Date	11/16/2005		

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



A33081-R 072771.0106
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Tsang et al.

Serial No.: 09/633,034

Examiner: Helms, L.R.

Filed : August 4, 2000

Group Art Unit: 1642

For : MONOCLONAL ANTIBODIES AGAINST HUMAN COLON CARCINOMA-
ASSOCIATED ANTIGENS AND USES THEREFOR

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited on November 16 2005 with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria VA 22313-1450

Lisa B. Kole

35,225

Attorney Name

PTO Registration No.

November 16 2005

Signature

Date of Signature

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicants respectfully request that the document listed below be considered by the Examiner and made of record in the above-referenced application. The references cited below and in the accompanying Form P.T.O. 1449 were cited

533965

-1-

11/21/2005 HLE333 00000010 09633034

01 FC:1806

180.00 OP

in an Official Action in Japanese Patent Application No. 510,288/1966 which claims priority to the present re-issue application. Applicants state herein as required under 37 C.F.R. §§ 1.97 (c)(1) and (e)(1), that each item of information contained in this supplemental information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

The numbering of references continues from the last reference number 47, cited in the Information Disclosure Statement filed August 10, 2005.

48) A.H. Bartal, J. Wolf, H. Lichtig, E. Agranovsky, R. Levy, H. Kerner, V. Bychkov, O. Saric, M. Wolff, Y. Hirshaut, M. Monizur, M. Arlen and L. Pertschuk. Proc. Am. Assoc. Cancer Res. 1994, Mar. Vol 35, Abstract 103, "Comparison of immunostaining of colonic neoplasms with PCA 31.1, PCA 33.28, B72-3 and anti-CEA monoclonal antibodies."

49) Myron Arlen, J.D. and Kwong Y. Tsang. J. Surg. Oncol. 1993, Vol 54, pages 103-108, "Monoclonal Antibodies and Their Role in Modulation of the Immune Response."

50) M. Arlen, A. C. Hollinshead and K. Y Tsang .Ann. New York Acad Sci 1993, Vol, 690, pp. 374-375; "Identification and Characterization of a Colon Tumor-Associated Antigen."

51) M. Arlen, K.Y. Tsang, A. Bartal, J. Wolf and O. Saric. Antib. Immunoconj. Radiopharm 1991, Vol 4, pp. 895-905; "Monoclonal Antibodies to Immunoreactive Tumor Associated Antigen (TAA) from Human Colon Carcinoma."

52) D.L. Xu, S. Wei, K.Y. Tsang. FASEB J, 1991, Vol J5, No. 4, Abstract 2109; "Construction of a Mouse/Human Chimeric Light Chain From Murine Monoclonal Antibody 33.28 Against Colorectal Carcinoma-Associated Antigens."

53) Myron Arlen and Alfred K. Tsang. J. Tumor Marker Oncol. 1990, Vol 5, No. 4, pp. 313-319; "The Nature of the Monoclonal Antibodies Derived from Immunogenic Membrane Antigen of Human Colon Carcinoma Origin."

54) Kwong Y. Tsang, M.F. LaVia, L. Bishop, D.L. Xu, E. Johnson and M. Arlen. FASEB J., 1988, Vol. J2, No. 5, Abstract 6815; "Colon Carcinoma Associated Antigens Characterized by Monoclonal Antibodies."

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that the listed documents are material or constitute "prior art." If the Examiner applies the document(s) as prior art against any claim in the application and applicants determine that the cited document(s) do not constitute "prior art" under United States law, applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the document(s).

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed document(s), should the document(s) be applied against the claims of the present application.

Applicants believe that no fee in addition to the enclosed fee of \$ 180.00 under 37 C.F.R § 1.17(p) is due in connection with the filing of this Information Disclosure Statement. However, should any fee be required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit any overpayments made, to Deposit Account 02-4377. A duplicate copy of this paper is enclosed.


Respectfully submitted,
BAKER BOTTS L.L.P.

By 

Lisa B. Kole
Patent Office Reg. No. 35,225
Attorney for Applicant

30 Rockefeller Plaza
New York, NY 10012-4498
(212)-408-2500

Enclosure

Form PTO-1449 U.S. Department of Commerce
(Rev. 3-83) Patent and Trademark Office**INFORMATION DISCLOSURE STATEMENT
BY APPLICANT**

(Use several sheets if necessary)

Atty. Docket No.
A33081-R 072771.0106Serial No.
09/633,034Applicant
Tsang et al.Filing Date
August 4, 2000Group
1642Examiner
To Be Assigned

L.R. Helms

U.S. PATENT DOCUMENTS

*Exam. Initial.	No.		Document No.	Date	Name	Class	Subclass	Filing Date if Approximate.

FOREIGN PATENT DOCUMENTS

Exam Initial	No.		Document No.	Date	Country	Class	Subclass	Translation Yes No

Exam Initial	N o.		OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, Etc.)					
		48	Proc. Am. Assoc. Cancer Res. 1994, Mar. Vol 35, Abstract 103, "Comparison of immunostaining of colonic neoplasms with PCA 31.1, PCA 33.28, B72-3 and anti-CEA monoclonal antibodies". A.H. Barta, J. Wolf, H. Lichtig, E. Agranovsky, R. Levy, H. Kerner, V. Bychkov, O. Saric, M. Wolff, Y. Hirshaut, M. Monizur, M. Arlen and L. Pertschuk.					
		49	J. Surg. Oncol. 1993, Vol 54, pages 103-108, "Monoclonal Antibodies and Their Role in Modulation of the Immune Response", Myron Arlen, J.D. and Kwong Y. Tsang, Ph.D.					
		50	Ann. New York Acad Sci 1993, Vol, 690, pp. 374-375; "Identification and Characterization of a Colon Tumor-Associated Antigen". M. Arlen, A. C. Hollinshead and K. Y Tsang.					

NY02:534047.1

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[illegible]

Examiner

Date Considered

* Examiner: Initial citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.